Abstract 17222: Safety, Tolerability and LDL-C Reduction With LIB003 a Novel Anti-PCSK9 Recombinant Fusion Protein: Results of Open-Label Extension Phase 2B Study

Introduction: LIB003 (LIB) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin which offers small injection volumes for monthly (Q4W) dosing. We evaluated l...